February 25, 2026
The Ninth Circuit ruled against a lower court Wednesday in saying pharmaceutical giant Eli Lilly does not owe $278 million in royalties to an Arizona company for insulin-brands sales, saying an agreement between the companies did not cover insulin products Eli Lilly made using a certain yeast expression technology.
October 20, 2021
A federal judge has determined that Eli Lilly owes an Arizona company a portion of the billions of dollars in sales from its insulin brands, citing a 1992 royalty agreement that allowed the pharmaceutical giant to use a certain strain of yeast to help develop the drugs.